DarioHealth Corp. (DRIO)
| Market Cap | 292.02M |
| Revenue (ttm) | 7.58M |
| Net Income (ttm) | -33.10M |
| Shares Out | 15.48M |
| EPS (ttm) | -5.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $18.09 |
| Previous Close | $18.87 |
| Change ($) | -0.78 |
| Change (%) | -4.13% |
| Day's Open | 18.78 |
| Day's Range | 17.42 - 19.14 |
| Day's Volume | 159,300 |
| 52-Week Range | 5.55 - 31.85 |
NEW YORK, April 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of a new virtual care initiative with MediOrbis...
NEW YORK, March 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 ...
DarioHealth (NASDAQ:DRIO) releases its next round of earnings this Tuesday, March 09. Here is Benzinga's essential guide to DarioHealth's Q4 earnings report.
NEW YORK, March 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quart...
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive Officer, is schedu...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the signing of a definitive agreement to acquire digi...
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of DarioHealth Corp. (Nasdaq: DRIO) concerning the Company and its directors' and officers' possible ...
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to pro...
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2020 Results - Earnings Call Transcript
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter 2020 and provided a ...
DRIO offers a diabetes management solution that is highly rated, provides strong ROI for all parties, and simpler than main competitor Livongo. Seasoned executives in the digital therapeutics space have...
NEW YORK, Oct. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company's digital therapeutics...
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2020 Results - Earnings Call Transcript
Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- DarioHealth Corp.
NEW YORK, July 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction with accredi...
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient mo...
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2020 Results - Earnings Call Transcript
Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2019 Results - Earnings Call Transcript
Shares of digital health company DarioHealth Corp (NASDAQ: DRIO) are advancing strongly Tuesday.
Shares of DarioHealth Corp. DRIO, +23.40% jumped 103% as it announced that Walmart would sell DarioHealth's digital diabetes management system online.
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2019 Results - Earnings Call Transcript
DarioHealth's (DRIO) CEO Erez Raphael on Q2 2019 Results - Earnings Call Transcript
DarioHealth's (DRIO) CEO Erez Raphael on Q1 2019 Results - Earnings Call Transcript
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2018 Results - Earnings Call Transcript
About DRIO
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic ... [Read more...]
| Industry Diagnostics & Research | Founded 2011 |
| Stock Exchange NASDAQ | Ticker Symbol DRIO |
Financial Performance
In 2020, DarioHealth's revenue was $7.58 million, an increase of 0.22% compared to the previous year's $7.56 million. Losses were -$29.45 million, 66.0% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for DarioHealth stock is "Strong Buy." The 12-month stock price forecast is 29.28, which is an increase of 61.86% from the latest price.